Get the Stockscreener App
5.99
0.08%
0.03
Solid Biosciences Inc stock is traded at $5.99, with a volume of 52,056.
It is up +0.08% in the last 24 hours and up +10.67% over the past month.
Solid Biosciences Inc is a life science company. It is engaged in the manufacturing of specialty and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. The company's pipeline products are the SB-001 and solid suit. The Company's singular focus is on developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases. The company has categorized its programs into corrective therapies, disease-modifying therapies, and assistive devices.
See More
Previous Close:
$5.96
Open:
$6.06
24h Volume:
52,056
Relative Volume:
0.04
Market Cap:
$466.44M
Revenue:
$14.79M
Net Income/Loss:
$-102.44M
P/E Ratio:
-1.9704
EPS:
-3.04
Net Cash Flow:
$-91.73M
1W Performance:
+8.85%
1M Performance:
+10.67%
6M Performance:
+120.93%
1Y Performance:
-1.40%
1-Day Range:
$5.95
$6.18
1-Week Range:
$5.215
$6.79
52-Week Range:
$2.41
$7.37
Solid Biosciences Inc Stock (SLDB) Company Profile
Name
Solid Biosciences Inc
Sector
Industry
Phone
617-337-4680
Address
500 RUTHERFORD AVENUE, CHARLESTOWN, MA
Compare SLDB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SLDB
Solid Biosciences Inc
|
5.99 | 464.10M | 14.79M | -102.44M | -91.73M | -3.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
406.19 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
458.57 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
543.50 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
797.00 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
326.40 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Solid Biosciences Inc Stock (SLDB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-26-25 | Initiated | Citigroup | Buy |
| Jan-08-25 | Initiated | Truist | Buy |
| Dec-13-24 | Initiated | Wedbush | Outperform |
| Dec-10-24 | Initiated | JMP Securities | Mkt Outperform |
| Jul-15-24 | Upgrade | JP Morgan | Neutral → Overweight |
| Jun-24-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| May-31-24 | Resumed | Piper Sandler | Overweight |
| Mar-28-24 | Initiated | William Blair | Outperform |
| Mar-15-24 | Initiated | Citigroup | Buy |
| Mar-14-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-08-23 | Initiated | H.C. Wainwright | Buy |
| Jul-12-21 | Initiated | Piper Sandler | Neutral |
| May-27-21 | Initiated | Jefferies | Buy |
| Mar-16-21 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Mar-09-21 | Initiated | Barclays | Overweight |
| Jan-08-21 | Upgrade | Credit Suisse | Underperform → Neutral |
| Jul-28-20 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| May-07-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Oct-11-19 | Initiated | Evercore ISI | Outperform |
| Aug-29-19 | Downgrade | Citigroup | Neutral → Sell |
| Aug-19-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Aug-16-19 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| May-14-19 | Downgrade | Credit Suisse | Neutral → Underperform |
| May-14-19 | Downgrade | Goldman | Neutral → Sell |
| Feb-08-19 | Upgrade | Citigroup | Sell → Neutral |
| Feb-08-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Nov-06-18 | Initiated | Citigroup | Sell |
| Sep-06-18 | Initiated | Credit Suisse | Neutral |
View All
Solid Biosciences Inc Stock (SLDB) Latest News
Is Solid Biosciences Inc. stock in correction or buying zone2025 Technical Overview & Weekly High Return Stock Forecasts - newser.com
Why Solid Biosciences Inc. stock is trending among retail traders2025 Market Overview & Free Weekly Chart Analysis and Trade Guides - newser.com
Using portfolio simulators with Solid Biosciences Inc. includedWeekly Investment Report & Growth Oriented Trading Recommendations - newser.com
Price momentum metrics for Solid Biosciences Inc. explainedQuarterly Trade Summary & Capital Efficiency Focused Ideas - newser.com
Is Solid Biosciences Inc. stock ready for a breakoutTrade Volume Report & Daily Technical Stock Forecast Reports - newser.com
Solid Biosciences (NASDAQ:SLDB) Upgraded at Wall Street Zen - MarketBeat
Why Solid Biosciences Inc. stock is favored by pension fundsTrade Volume Report & Growth Oriented Trade Recommendations - newser.com
Visual trend scoring systems applied to Solid Biosciences Inc.Layoff News & Accurate Intraday Trading Signals - newser.com
Duchenne Muscular Dystrophy Drugs Market Global Forecast - GlobeNewswire
Duchenne Muscular Dystrophy Drugs Market Global Forecast 2025-2032: Sarepta, Pfizer, BioMarin, Roche, Bayer, Solid Biosciences, Cytokinetics, and NS Pharma Drive Innovation and Commercial Expansion - Yahoo Finance
Solid Biosciences (NASDAQ:SLDB) Receives "Sell (D-)" Rating from Weiss Ratings - MarketBeat
Will Solid Biosciences Inc. stock attract ESG investors2025 Earnings Impact & Real-Time Volume Analysis Alerts - newser.com
Solid Biosciences (NASDAQ:SLDB) Trading 22% HigherTime to Buy? - MarketBeat
Solid Biosciences Raises up to $50 Million in Series C Financing - Bain Capital
Can Solid Biosciences Inc. stock deliver sustainable ROE2025 Earnings Impact & High Accuracy Investment Signals - newser.com
Trend analysis for Solid Biosciences Inc. this weekForecast Cut & Free Weekly Chart Analysis and Trade Guides - newser.com
Is Solid Biosciences Inc. forming a bottoming baseMarket Trend Report & AI Optimized Trading Strategy Guides - newser.com
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Solid Biosciences to Present at Upcoming Scientific Meetings - GlobeNewswire
Next-Gen Duchenne Muscular Dystrophy Treatment Update: Solid Bio's Gene Therapy Trial Results Coming - Stock Titan
116,150 Restricted Stock Units: Solid Biosciences Awards Equity Grants to Key New Personnel - Stock Titan
Electrovaya Inc Stock Analysis and ForecastDividend Stability Analysis & Stay Invested. Stay Smart. - earlytimes.in
Solid Biosciences Inc. stock volume spike explainedMarket Performance Summary & Consistent Profit Focused Trading Strategies - newser.com
Solid Biosciences Inc. (NASDAQ:SLDB) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
What analysts say about Solid Biosciences Inc stockUtilities Sector Analysis & Free Daily Investment Newsletter Subscription - earlytimes.in
Solid Biosciences to Present at 2025 Neuromuscular Study Group Annual Scientific Meeting - GlobeNewswire
Next-Gen DMD Gene Therapy Data: Solid Bio's SGT-003 Shows Promising Safety Profile at 90 Days - Stock Titan
Goldman Sachs Group Inc. Buys 43,910 Shares of Solid Biosciences Inc. $SLDB - MarketBeat
Solid Biosciences grants AAV-SLB101 license to Kinea Bio - MSN
Cantor Fitzgerald Sticks to Their Buy Rating for Solid Biosciences (SLDB) - The Globe and Mail
William Blair Maintains Solid Biosciences(SLDB.US) With Buy Rating - 富途牛牛
Solid Biosciences (SLDB) Partners with Kinea Bio for Muscular Dy - GuruFocus
Solid Biosciences Inc Stock (SLDB) Financials Data
Revenue
Net Income
Cash Flow
EPS
Solid Biosciences Inc Stock (SLDB) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Bain Capital Life Sciences Inv | 10% Owner |
Feb 19 '25 |
Buy |
4.03 |
1,000,000 |
4,030,000 |
5,034,582 |
| PERCEPTIVE ADVISORS LLC | Director |
Feb 19 '25 |
Buy |
4.03 |
5,000,000 |
20,150,000 |
11,833,539 |
| Adage Capital Management, L.P. | 10% Owner |
Feb 18 '25 |
Buy |
7.56 |
252,545 |
1,909,240 |
4,248,084 |
| Hanrahan Jessie | Chief Regulatory Officer |
Feb 14 '25 |
Sale |
3.96 |
3,079 |
12,193 |
19,281 |
| Brooks Gabriel | Chief Medical Officer |
Feb 14 '25 |
Sale |
3.96 |
3,256 |
12,894 |
22,812 |
| Tan Kevin | CFO & Treasurer |
Feb 14 '25 |
Sale |
3.96 |
3,164 |
12,529 |
32,250 |
| Howton David T | Chief Operating Officer |
Feb 14 '25 |
Sale |
3.96 |
5,561 |
22,022 |
24,789 |
| Herzich Paul | Chief Technology Officer |
Feb 14 '25 |
Sale |
3.96 |
2,688 |
10,644 |
18,388 |
| Cumbo Alexander | President and CEO |
Feb 14 '25 |
Sale |
3.96 |
11,365 |
45,005 |
60,717 |
| Ganot Ilan | Director |
Feb 14 '25 |
Sale |
3.96 |
1,711 |
6,776 |
14,839 |
2.81%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):